aTyr Pharma, Inc. (NASDAQ:LIFE) – Equities researchers at William Blair boosted their Q3 2017 earnings estimates for shares of aTyr Pharma in a note issued to investors on Tuesday. William Blair analyst Y. Xu now anticipates that the biotechnology company will post earnings per share of ($0.53) for the quarter, up from their previous estimate of ($0.58). William Blair also issued estimates for aTyr Pharma’s Q4 2017 earnings at ($0.56) EPS, FY2017 earnings at ($2.17) EPS, FY2018 earnings at ($2.66) EPS and FY2019 earnings at ($3.17) EPS.

aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.06.

TRADEMARK VIOLATION WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at

LIFE has been the subject of several other reports. BMO Capital Markets set a $4.00 target price on aTyr Pharma and gave the company a “hold” rating in a report on Tuesday. ValuEngine lowered aTyr Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, Zacks Investment Research raised aTyr Pharma from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has given a buy rating to the company. aTyr Pharma presently has a consensus rating of “Hold” and a consensus target price of $3.65.

Shares of aTyr Pharma (NASDAQ:LIFE) opened at 2.75 on Thursday. The firm’s market capitalization is $65.47 million. aTyr Pharma has a 1-year low of $2.10 and a 1-year high of $4.45. The company has a 50-day moving average price of $3.32 and a 200 day moving average price of $3.38.

An institutional investor recently raised its position in aTyr Pharma stock. EcoR1 Capital LLC raised its stake in shares of aTyr Pharma, Inc. (NASDAQ:LIFE) by 134.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,292,659 shares of the biotechnology company’s stock after buying an additional 1,315,673 shares during the period. aTyr Pharma accounts for approximately 2.0% of EcoR1 Capital LLC’s investment portfolio, making the stock its 13th largest position. EcoR1 Capital LLC owned 9.65% of aTyr Pharma worth $8,024,000 as of its most recent filing with the SEC. 47.03% of the stock is currently owned by institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Earnings History and Estimates for aTyr Pharma (NASDAQ:LIFE)

Receive News & Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related companies with's FREE daily email newsletter.